Loading
Life sciences · Journal article
Journal of Nanobiotechnology · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignancies due to its aggressive nature, poor prognosis and lack of targeted treatment. Sorafenib is a clinical first-line multi-targeted tyrosine kinase inhibitor (TKI) drug for advanced HCC, but its responsiveness limits its long-term utility. Tumor stemness and epithelial-mesenchymal transition (EMT) contribute to TKI drug sensitivity. Sox4 can promote tumor resistance by endowing cancer cells with stemness and invasive properties. Therefore, reversing tumor stemness gene expression and improving tumor malignant phenotype is a promising strategy to increase the sensitivity of HCC to sorafenib. Here, we constructed a functional nanoplatform LE-T@SOR/shSox4 combines gene therapy with targeted therapy, and selectively delivers sorafenib and knockdown plasmid to tumor site. In vitro experiments demonstrate that LE-T@SOR/shSox4 can effectively inhibit the expression of stemness-related genes, reverse the EMT process and promote differentiation in HCC, thereby increasing the drug sensitivity of HCC to sorafenib. Compared with the control groups, administration of LE-T@SOR/shSox4 dramatically suppressed CD133 expression, reduced the tumor size, and effectively improved the antitumor effect of sorafenib in vivo. In conclusion, our study provides an effective therapeutic strategy for the clinical treatment of HCC.